Ki te whakaaro koe ki te rongoā GLP-1 mō te whakaheke taumaha, ehara i te mea ko te kōwhiri i waenganui i te tango i te werohanga, kaore rānei. I te tau 2026, kei reira ngā kōwhiringa ā-waha kua whakaaetia e te FDA, tae atu ki ngā papa semaglutide o ia rā me te orforglipron (Foundayo), i te taha o ngā rongoā GLP-1 werohanga kua wātea mai mō ngā tau.
He nui ake ētā kōwhiringa māu, engari ka āta māramatia hoki te whakatau.
Āe, ka mārama ake pea te pire ki te kore koe e pai ki ngā ngira. Āe, ka mārama ake pea te werohanga ki te kore koe e hiahia ki te tango rongoā ia rā. Katahi ka puta te pātai mō te utu, ka taea te rereke te nui i runga i te rongoā, te kaha o te rongoā, te inihua, me te mea kei te utu moni koe.
Ka nui hoki ngā hua. E whakaatu ana ngā whakamātau haumanu i te whakaheke taumaha nui ki ngā rongoā GLP-1 ā-waha me te werohanga, engari ka puta ngā tau mai i ngā rangahau rerekē, kāore hoki e tika kia kiia he whakataetae tika.
TL;DR: Ngā Matapopore Nui
- Kei te wātea kē ngā rongoā GLP-1 hei pire me te werohanga mō ngā whakamahinga whakahaere taumaha.
- Kei te wātea a Wegovy (semaglutide) hei werohanga kotahi i te wiki me te papa o ia rā i te United States.
- Ko Foundayo (orforglipron) he GLP-1 ā-waha kotahi i te rā i whakaaetia e te FDA i te Paenga-whāwhā 2026 mō ngā pakeke he momo kikī, he taumaha rawa rānei, me tētahi mate hauora e pā ana ki te taumaha.
- Kua whakaatu ngā whakamātau haumanu i te whakaheke taumaha nui ki te semaglutide ā-waha, te orforglipron, me te semaglutide werohanga, engari i whakamahia e ngā whakamātau ngā rōpū rerekē, ngā rongoā, me ngā hoahoa rangahau.
- I te tau 2026, ka timata te utu o te pire Wegovy ki te $149 ia marama, i te mea ka timata te utu werohanga Wegovy ki te $349 ia marama. Ka timata hoki te utu Foundayo ki te $149 ia marama.
- He pai ngā pire ki te karo i ngā werohanga, engari kei ētahi rongoā GLP-1 ā-waha ngā tohutohu inenga motuhake. He rereke a Foundayo i te mea ka taea te tango i ngā wā katoa o te rā me te kore he here kai, wai rānei.
- Ka taea e ngā pire me ngā werohanga te whakaputa i ngā pānga taha o te pūnaha kūnatu pēnei i te ruaki, te korere, te matenana, me te ruaki.
Nā te pātai mō ngā rongoā GLP-1 mō te whakaheke taumaha? Tāpui he $39 te utu mō te toro hauora ipurangi ki August AI. Ka taea e tētahi kaimātai hauora kua raihana ki te US te tiro i tō hītori hauora me te matapaki mena kei te tika te rongoā GLP-1 mōu, me te tiki rongoā i te taua rā puta noa i ngā whenua 50 katoa ina tika ana te rongoā. Kāore te toro i te whakamana i te rongoā. Ko te whakahaere taumaha GLP-1 roa ka pai ake te tiaki e tō kaiwhakahaere hauora tuatahi, tō endocrinologist rānei e taea te aro turuki i te anga whakamua, te whakarerekē i te inenga, me te whakarite i te tiaki kē. Kāore te hauora o August e tuku rongoā compounded, kāore rānei i whakaaetia e te FDA GLP-1.
He aha te rereketanga i waenganui i te pire GLP-1 me te werohanga?
E rua ngā momo e mahi ana i runga i te ara GLP-1, e āwhina ana ki te whakahaere i te hiahia kai, te kai, me te huka toto.
Ko te tino rereketanga nui ko te āhua o te tango i a rātou.
Ko ngā rongoā werohanga pēnei i a Wegovy (semaglutide) ka tukuna ki raro i te kiri, ā, ka kotahi te wiki. Kāore koe e maumahara ki te pire ia rā.
Ko ngā rongoā ā-waha ka tangohia ia rā. I te tau 2026, ko ngā kōwhiringa nui e rua ko te semaglutide ā-waha e hokona ana hei papa Wegovy me te orforglipron e hokona ana hei Foundayo.
Kei roto i te papa Wegovy te semaglutide, te matū kaha rite ki te putanga werohanga. Kei roto i ngā tohutohu whakahaere a te FDA ngā tohutohu mō te huri i waenganui i te papa 25 mg me te werohanga 2.4 mg, ahakoia kāore e rite ngā tikanga inenga.
Kei roto i Foundayo te orforglipron, he GLP-1 receptor agonist rerekē. Kaore i rite ki te semaglutide ā-waha, kaore a Foundayo e hiahia ana ki te kai, ki te wai rānei i te taha o te werohanga.
Ngā Kōwhiringa Pire GLP-1 ā-Waha i te tau 2026
Ko te kupu "pire GLP-1 ā-waha" inaianei he nui atu i tētahi rongoā.
Ngā Papa Wegovy
Kei roto i ngā papa Wegovy te semaglutide, ā, kei te wātea hei papa 1.5 mg, 4 mg, 9 mg, me te 25 mg. Ko te papa 25 mg te papa teitei ake e whakamahia ana mō te whakaheke taumaha.
Ka tangohia te papa kotahi i te rā. Kua whakaatu te semaglutide ā-waha i te whakaheke taumaha nui i ngā whakamātau haumanu. I te whakamātau OASIS 4, ko ngā tangata he taumaha rawa atu, he momo kikī rānei i tango i te 25 mg o te semaglutide ā-waha i te toharite 13.6% te whakarerekētanga o te taumaha i te wiki 64, ka whakaritea ki te 2.2% ki te placebo. He maha ngā pānga taha o te pūnaha kūnatu, ka puta ki te 74% o ngā tangata e tango ana i te semaglutide ā-waha ka whakaritea ki te 42.2% e tango ana i te placebo.
Foundayo (orforglipron)
Ko Foundayo he rongoā GLP-1 ā-waha kotahi i te rā i whakaaetia e te FDA i te Paenga-whāwhā 2026 mō ngā pakeke he momo kikī, he taumaha rawa rānei, me te kotahi te mate hauora e pā ana ki te taumaha.
Ko tētahi rereketanga nui ko te āhua o te tango. Ka taea te tango a Foundayo i ngā wā katoa o te rā me te kore he here kai, wai rānei.
I roto i tētahi rangahau nui 72-wiki ki ngā pakeke momo kikī kāore he mate huka, ko te whakaheke taumaha toharite i waenganui i te 7.5% me te 11.2% i runga i te inenga orforglipron, ka whakaritea ki te 2.1% ki te placebo. I te inenga teitei ake i rangahaua, 54.6% o ngā kaiuru i ngaro te 10% o tō rātou taumaha tinana.
He pai ēnei tau ki te mārama ki te kaha o te rongoā, engari kāore e tika kia whakamahia kia kii ai ka puta te orforglipron i ngā hua rite ki te semaglutide ā-waha me te werohanga. I rangahaua ngā rongoā i roto i ngā rangahau rerekē me ngā hoahoa me ngā rōpū tūroro rerekē.
Me pēhea te whakataetae o ngā pire ki ngā werohanga GLP-1 mō te whakaheke taumaha?
Kua rangahaua nuitia te semaglutide werohanga mō te whakahaere taumaha.
I te rangahau nui STEP 1, ko ngā pakeke momo kikī, he taumaha rawa rānei i whiwhi i te semaglutide werohanga 2.4 mg kotahi i te wiki i ngaro te toharite o te 15% o tō rātou taumaha timatanga i muri i te 68 wiki, ka whakaritea ki te 2.4% ki te placebo.
Kua whakaputa hoki te semaglutide ā-waha i te whakaheke taumaha nui. I te OASIS 4, i whakaputa te papa 25 mg i te toharite o te 13.6% te whakaheke taumaha i te wiki 64.
I whakaputa te orforglipron i te toharite o te 11.2% te whakaheke taumaha i te 72 wiki i te rangahau momo kikī nui.
Hei tirohanga tuatahi, ka taea e koe te whai i ēnei ōrau ka kii atu ka nui ake te whakaheke taumaha o te werohanga i ngā pire. Heoi anō he māmā rawa tērā.
Kāore ēnei i te whakataetae tika. He rerekē ngā kaiuru, he rerekē ngā wā maimoatanga, ā, he rerekē ngā rongoā me ngā hoahoa rangahau. Ka rereke hoki ngā urupare a te tangata.
Ko te take nui ake ko te taea o ngā rongoā GLP-1 ā-waha me te werohanga ki te whakaputa i te whakaheke taumaha nui, ka whakamahia ki ngā tūroro tika, me te kai me te korikori tinana.
Utu pire Wegovy ki te utu werohanga Wegovy
Ko te utu te tētahi o ngā rereketanga nui hei whakaaro.
Mai i te tau 2026, ka whakaatu te utu o te tangata ake o Novo Nordisk i te pire Wegovy:
| Te ahua o Wegovy | Utu tangata ake kua whakaatuhia |
|---|---|
| Pire Wegovy, 1.5 mg | $149/marama |
| Pire Wegovy, 4 mg | $149 ki te $199/marama i runga i te tuku |
| Pire Wegovy, 9 mg | $299/marama |
| Pire Wegovy, 25 mg | $299/marama |
| Werohanga Wegovy | $349/marama mō ētahi werohanga |
| Werohanga Wegovy HD | $399/marama |
Ēnei ngā utu o te kaihanga mō te tangata ake, ā, ka whai herenga tōtika, tōtika rānei ngā tuku. Ka taea te rereke te utu inihua.
Na reira ki te rapua e koe te utu pire Wegovy, kāore he tau kotahi te whakautu i te tau 2026. Ka puta te utu o te tangata ake i runga i te kaha o te papa me te tuku o nāianei.
Ka taea te inihua te whakarerekē i te tatauranga. Ko te rongoā teitei ake te utu ka iti ake pea te utu o waho mō tētahi e inihua ana, ko tētahi kāore he inihua ka utu te katoa te utu o te tangata ake.
E hia te utu o Foundayo?
Ko Foundayo tētahi atu kōwhiringa GLP-1 ā-waha hei whakaaro mō te utu GLP-1 i te tau 2026.
E whakaatu ana a Lilly i tēnei wā te utu o te tangata ake ka timata ki te $149 ia marama. Ka rereke ngā utu kua whakaatuhia i runga i te inenga, ka timata mai i te $149 ki te $349 ia marama. Ko ētahi inenga he tuku penapena poto tae noa ki te Hakihea 31, 2026.
Ka taea e ngā tangata whai inihua arumoni te utu i te $25 ia marama mā te mahi penapena a Lilly, ahakoia ka whai herenga tōtika.
Kāore tērā e kii ana ka utu a Foundayo ki ia tūroro $149, $25 rānei. Ka puta tō utu tūtahi i runga i te inihua, te tōtika, te inenga, te whare rongoā, me te mahi penapena motuhake e wātea ana ki a koe.
Orforglipron ki semaglutide: he rite rāua?
Kāore.
E rua ngā mahi a Orforglipron me semaglutide i runga i te GLP-1 receptor, engari he rongoā rerekē rāua.
Ko Semaglutide te matū kaha i roto i a Wegovy. Kei te wātea hei werohanga, ā, inaianei, hei papa mō ētahi whakamahinga.
Ko Orforglipron te matū kaha i roto i a Foundayo. He GLP-1 receptor agonist ā-waha iti-mōkete.
Kei reira ētahi raraunga whakataetae tika i waenganui i te orforglipron me te semaglutide ā-waha, engari ko te tino herenga ko te rangahau i roto i ngā tangata he mate huka momo 2, ehara i te whakataetae whakaheke taumaha tika i waenganui i ngā inenga momo kikī kua whakaaetia.
I roto i te rangahau ACHIEVE-3 a Lilly, i whakaputa te orforglipron 17.2 mg i te nui ake te hekenga o te A1C me te taumaha tinana i te semaglutide ā-waha 14 mg i roto i ngā pakeke he mate huka momo 2. Kua ripoatahia ēnei hua e Lilly, nāna i tautoko te rangahau.
Ka taea e tērā rangahau te whakamārama me pēhea te whakataetae o ngā rongoā e rua ki te maimoatanga mate huka, engari kāore e tika kia hurihia hei kōrero ka puta tētahi rongoā te nui o te whakaheke taumaha mō ia tangata.
Ngā pire ki ngā werohanga: ngā whakangāwha o ia rā
Ka pai ngā pire ki te kore koe e hiahia ki ngā werohanga
Kāore ētahi tangata e pai ki te werohanga rongoā ki tō rātou kiri. Ka tangohia e te GLP-1 ā-waha tērā wāhanga o te maimoatanga.
Engari kāore he pire e āta mārama. Ko te rongoā o ia rā me maumahara ki te tango ia rā. Ko ētahi tikanga semaglutide ā-waha kei a rātou ngā tohutohu motuhake mō te tango i te rongoā, i te mea ka taea te tango a Foundayo me te kore he here kai, wai rānei.
Ka taea te iti ake te inenga o ngā werohanga
Ka tangohia te werohanga Wegovy kotahi i te wiki.
Mō tētahi e uaua ana ki te maumahara ki ngā rongoā o ia rā, ka taea te werohanga ia wiki te uru ngāwari ki tō rātou tikanga. Ka karo hoki i ngā raruraru whakauru e puta ana i te tango rongoā mā te waha. Ko te whakangāwha ko te tango i te werohanga.
Ka taea ngā pānga taha ki te rua
Ko te ruaki, te korere, te matenana, te ruaki, te mamae puku, me ētahi atu mate pūnaha kūnatu kei roto i ngā pānga taha kua ripoatahia mō ngā rongoā GLP-1.
Mō Foundayo, ka puta ngā tauhohenga pūnaha kūnatu ki te 60% ki te 69% o ngā kaiuru puta noa i ngā inenga i rangahaua ka whakaritea ki te 37% ki te placebo.
Kei roto hoki i ngā mōhiohio whakahaere a Wegovy ngā whakatūpato me ngā aukati nui, tae atu ki tētahi whakatūpato pouaka e pā ana ki ngā pukupuku kura C ate o te taiaki i runga i ngā kitenga i roto i ngā rodents, me ngā whakatūpato mō te pakapaka, te mate gallbladder, te kino o te whatukuhu e pā ana ki te maroke, me ngā tauhohenga pūnaha kūnatu nui.
Kāore ēnei rongoā e tika mō te katoa, ā, me tirotiro tētahi kaimātai hauora i tō hītori hauora i mua i te whakahaerenga.
Me pēhea ngā pire GLP-1 compounded, werohanga rānei?
Ka taea te raruraru ngā whakataetae utu ina uru mai ngā hua compounded.
Ka taea te panui i te semaglutide compounded me ētahi atu hua GLP-1 kāore i whakaaetia e te FDA i ngā utu iti ake i ngā rongoā waitohu. Engari ehara i te mea rite te whakaaetanga a te FDA me te compounding.
E kii ana te FDA kei te compounded GLP-1 drugs kāore i te whakaaetia e te FDA, ā, kāore hoki e tirohia e te tari mō te haumaru, te whai hua, me te kounga i mua i te hokonga. Kua ripoata hoki te tari i ngā take e pā ana ki ngā hapa inenga me ngā hua compounded teka.
Kāore te utu panui iti e kii ki a koe mena kei te tika te rongoā mō koe, mena he hua kua whakaaetia e te FDA.
Na, ko tehea momo GLP-1 hei matapaki māu ki tō kaimātai hauora?
Kāore he kōwhiringa pire-ki-werohanga kotahi e tika ana mō te katoa.
Ka puta te whakatau i runga i ngā whāinga whakahaere taumaha, te hītori hauora, ētahi atu rongoā, te inihua, te tahua moni, ngā manakohanga inenga, me te āhua o te pai o koe ki ngā werohanga.
Ki te whakataetae koe i tētahi pire GLP-1 ā-waha ki tētahi werohanga, pātai mō ngā mea e whā:
- Tūmanakohanga hua: He aha te nui o te whakaheke taumaha e tika ana mō tētahi o tō hītori hauora?
- Utu: He aha tō utu ia marama i muri i te inihua, penapena kaihanga rānei?
- Inenga: Ka pai ake te pire o ia rā, te werohanga ia wiki rānei ki tō tikanga?
- Haumaru: Kei a koe ētahi mate hauora, kei te tango koe i ētahi rongoā e pā ana ki te GLP-1 tika mōu?
Ka taea hoki e koe te whakataetae te utu rongoā ki te utu o ngā toro rongoā, ngā taiwhanga, me te aroturuki ka hiahiatia i te wā o te maimoatanga.
Ngā Pātai Auau
Kei te whai hua te pire GLP-1 pera i te werohanga?
Ka taea e ngā rongoā GLP-1 ā-waha te whakaputa i te whakaheke taumaha nui, engari kāore e taea te whakamahi i ngā hua mai i ngā rangahau motuhake hei whakatau kei te whai hua te pire pera i te werohanga. Kua whakaputa te semaglutide ā-waha, te orforglipron, me te semaglutide werohanga i te whakaheke taumaha nui i roto i ngā rangahau haumanu.
He iti ake te utu o te pire Wegovy i te werohanga?
I raro i te utu o te tangata ake o Novo Nordisk i te tau 2026, he iti ake te utu o ētahi papa Wegovy i te utu o te tangata ake kua whakaatuhia mō te werohanga. Ka taea te rereke te nui o tō utu ki te whai inihua koe, ki te tika rānei koe mō tētahi tuku penapena.
E hia te utu o te GLP-1 ā-waha i te tau 2026?
Kāore he utu pire GLP-1 kotahi. Ko te utu o te tangata ake o te kaihanga o nāianei ka timata i te $149 ia marama mō ngā papa Wegovy me Foundayo, engari ka nui ake te utu o ngā inenga teitei ake. Ka taea te whakarerekē nui te utu e te inihua me ngā mahinga penapena.
He rite a orforglipron ki semaglutide?
Kāore. He GLP-1 receptor agonists rerekē a Orforglipron me semaglutide. Ko Orforglipron te matū kaha i roto i a Foundayo, i te mea ko semaglutide te matū kaha i roto i a Wegovy.
Ka taea te huri mai i te werohanga Wegovy ki te pire?
Kei roto i ngā tohutohu whakahaere a Wegovy a te FDA ngā tohutohu mō te huri i waenganui i te werohanga Wegovy 2.4 mg me te papa 25 mg. Me mahi te huringia i runga i ngā tohutohu whakahaere me ngā tohutohu a tō kaimātai hauora, kaua kia tangohia noatia ngā momo e rua tahi.
Te take katoa
Ko te taenga mai o ngā rongoā GLP-1 ā-waha ka hoatu he huarahi kē atu ki te tangata ki te whakatata atu ki te whakahaere taumaha me te kore he werohanga ia wiki. I te tau 2026, kei roto i ngā kōwhiringa ā-waha matua ngā papa Wegovy kei roto te semaglutide me Foundayo kei roto te orforglipron.
Ka taea te nui te rereketanga o te utu, āta ki te hunga e utu ana i waho o te pukoro. Engari ko te utu tētahi wāhanga o te whakatau. Ko te tikanga inenga, ngā pānga taha, te hītori hauora, te inihua, me te hua e tatarihia ana, ka nui katoa.
Ā, ahakoa e whakaatu ana ngā whakamātau haumanu i ngā hua whakamīharohiro mō ngā pire me ngā werohanga, kāore ngā rangahau e whakawhitiwhiti. Kāore te ōrau mai i tētahi rangahau e matapae ana i te nui o te ngaronga o tētahi atu tangata ki tētahi atu rongoā GLP-1.
Ko te whakataetae tika ehara i te mea kei te pai ake ngā pire, ngā werohanga rānei, engari he aha te maimoatanga kua whakaaetia, te inenga, me te kōwhiringa utu e uru ana ki tō āhua hauora me tō kaha ki te noho tika ki te maimoatanga.
